Drug Profile
Research programme: liver diseases therapeutics - Seres Therapeutics/Mayo Clinic
Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Seres Therapeutics
- Developer Mayo Clinic; Seres Therapeutics
- Class Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver disorders
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for research development in Liver-disorders in USA
- 07 Jun 2016 Seres Therapeutics and Mayo Clinic initiate a sponsored research agreement for new microbiome therapeutic candidates for liver diseases
- 07 Jun 2016 Early research in Liver disorders in USA (unspecified route)